(0.14%) 5 138.50 points
(0.09%) 38 475 points
(0.22%) 17 885 points
(-0.29%) $83.61
(1.72%) $1.956
(0.13%) $2 350.30
(0.59%) $27.70
(1.52%) $936.15
(-0.18%) $0.933
(-0.28%) $10.99
(-0.30%) $0.798
(1.16%) $92.94
Live Chart Being Loaded With Signals
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
今日成交量 | 7.09M |
平均成交量 | 7.51M |
市值 | 17.70B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.342 ( 2023-09-11 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.81 |
ATR14 | HKD0.00800 (0.11%) |
音量 相关性
China Medical System 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
China Medical System 相关性 - 货币/商品
China Medical System 财务报表
Annual | 2023 |
营收: | HKD8.01B |
毛利润: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2023 |
营收: | HKD8.01B |
毛利润: | HKD6.11B (76.24 %) |
EPS: | HKD0.980 |
FY | 2022 |
营收: | HKD9.15B |
毛利润: | HKD7.04B (76.89 %) |
EPS: | HKD1.330 |
FY | 2021 |
营收: | HKD8.34B |
毛利润: | HKD6.25B (74.93 %) |
EPS: | HKD1.221 |
Financial Reports:
No articles found.
China Medical System Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.337 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.274 (N/A) |
HKD0.342 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00693 | 2011-03-22 |
Last Dividend | HKD0.342 | 2023-09-11 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | HKD3.99 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.6 | -- |
Div. Sustainability Score | 9.69 | |
Div.Growth Potential Score | 5.90 | |
Div. Directional Score | 7.80 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2318.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
1286.HK | Ex Dividend Knight | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
0347.HK | No Dividend Player | 2023-06-01 | Sporadic | 0 | 0.00% | |
6099.HK | Ex Dividend Junior | 2023-07-14 | Annually | 0 | 0.00% | |
1848.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0874.HK | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
0023.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
2660.HK | Ex Dividend Knight | 2023-06-30 | Annually | 0 | 0.00% | |
1425.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
0512.HK | Ex Dividend Knight | 2023-06-09 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.300 | 1.500 | 4.01 | 6.01 | [0 - 0.5] |
returnOnAssetsTTM | 0.135 | 1.200 | 5.49 | 6.58 | [0 - 0.3] |
returnOnEquityTTM | 0.152 | 1.500 | 9.42 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.567 | -1.000 | 4.33 | -4.33 | [0 - 1] |
currentRatioTTM | 4.29 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.85 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.10 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0734 | -1.500 | 8.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.50 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0839 | -1.500 | 9.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.758 | 1.000 | 0.696 | 0.696 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.339 | 1.000 | 5.23 | 5.23 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.923 | 1.000 | 0.429 | 0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.320 | -0.256 | [0.5 - 2] |
Total Score | 9.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 6.91 | 1.000 | 9.40 | 0 | [1 - 100] |
returnOnEquityTTM | 0.152 | 2.50 | 9.63 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.010 | 2.00 | 9.66 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 9.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.021 | 2.00 | 9.66 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.567 | 1.500 | 4.33 | -4.33 | [0 - 1] |
pegRatioTTM | 0.342 | 1.500 | -1.052 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.312 | 1.000 | 4.69 | 0 | [0.1 - 0.5] |
Total Score | 5.90 |
China Medical System
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。